Neoadjuvant nivolumab has demonstrated efficacy in patients with mismatch repair-deficient, surgically resectable endometrial cancer.

CEL-SCI (CVM) announced that a third-party study published on March 6 in JAMA Oncology provided data that support Multikine’s use as a ...

During a live event, Sumanta K. Pal, MD, discusses the efficacy and safety findings from the CheckMate 274 trial of adjuvant ...

A recent study published in JAMA Oncology presents promising new data on a treatment regimen beneficial to patients with a ...

Journal of the American Medical Association study provides further evidence that Multikine can treat unmet need in ~70% of Head and Neck Patients.

Patients with resectable HNSCC were randomized to one of three neoadjuvant strategies: single-agent nivolumab, nivolumab/ipilimumab, or nivolumab/relatlimab. They categorized pTR by extent of ...

Lee and colleagues conducted the single-arm, phase 2 NIVEC study to assess the safety and efficacy of neoadjuvant nivolumab — an anti-PD-1 antibody — for women with resectable mismatch repair ...

Use of nivolumab (Opdivo) before chemotherapy was not associated with improved pathologic complete response (pCR) rates among patients with early triple-negative breast cancer (TNBC), but a 12-week ...